The AST/ALT (De Ritis) ratio as a significant prognostic factor in myelodysplastic syndrome

References

• Abbaszadeh Z, Çeşmeli S, Biray Avcı Ç. 2020. Crucial players in glycolysis: cancer progress. Gene. 726:144158. doi:10.1016/j.gene.2019.144158.
   PubMed Web of Science ®Google Scholar
• Ahmadabad MA, Naeimi A, Keymoradzadeh A, Faghani S, Ahmadabad MA, Boroujeni NA, Mohammadpour H, Saberi A. 2022. Evaluation of De Ritis (AST/ALT), ALP/ALT, and AST/ALP ratios as prognostic factors in patients with acute ischemic stroke. BMC Neurol. 22(1):450. doi:10.1186/s12883-022-02989-4.
   PubMed Web of Science ®Google Scholar
• An R, Ma S, Zhang N, Lin H, Xiang T, Chen M, Tan H. 2022. AST-to-ALT ratio in the first trimester and the risk of gestational diabetes mellitus. Front Endocrinol (Lausanne). 13:1017448. doi:10.3389/fendo.2022.1017448.
   PubMedGoogle Scholar
• Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. 2016. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 127(20):2391–2405. doi:10.1182/blood-2016-03-643544.
   PubMed Web of Science ®Google Scholar
• Balaian E, Wobus M, Bornhäuser M, Chavakis T, Sockel K. 2021. Myelodysplastic syndromes and metabolism. Int J Mol Sci. 22(20). doi:10.3390/ijms222011250.
   PubMed Web of Science ®Google Scholar
• Bejar R. 2014. Clinical and genetic predictors of prognosis in myelodysplastic syndromes. Haematologica. 99(6):956–964. doi:10.3324/haematol.2013.085217.
   PubMed Web of Science ®Google Scholar
• Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Ossa JEA, Nannya Y, Devlin S. M, Creignou M, Pinel P, Monnier L, Gundem G, Medina-Martinez GS, Domenico D, Jädersten M, Germing U, Sanz G, Loosdrecht A, Kosmider O, Follob MY, Thol F, Zamora L, Pinheiro RF, Pellagatti A, Elias HK, Haase D, Ganster C, Ades L, Tobiasson M, Palomo L, Porta MGD, Takaori-Kondo A, Ishikawa T, Chiba S, Kasahara S, Miyazaki Y, Viale A, Huberman K, Fenaux P, Belickova M, Savona MR, Klimek VM, Santos FPS, Boultwood J, Kotsianidis I, Santini V, Solé F, Platzbecker U, Heuser M, Valent P, Ohyashiki K, Finelli C, Voso MT, Shih LY, Fontenay M, Jansen JH, Cervera J, Gattermann N, Ebert BL, Bejar R, Malcovati L Cazzola M, Ogawa S, Hellström-Lindberg E, Papaemmanuil E. 2022. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evid 2022. 1(7):1–14. doi:10.1056/EVIDoa2200008.
   Google Scholar
• Cao L, Tang YJ, Gang M, Ma J, Qian WG, Xu QQ, Lv HT. 2021. AST-to-ALT ratio and coronary artery lesions among patients with Kawasaki disease. World J Pediatr. 17(6):659–668. doi:10.1007/s12519-021-00479-0.
   PubMed Web of Science ®Google Scholar
• De Ritis F, Coltorti M, Giusti G. 1957. An enzymic test for the diagnosis of viral hepatitis; the transaminase serum activities. Clin Chim Acta. 2(1):70–74. doi:10.1016/0009-8981(57)90027-X.
   PubMed Web of Science ®Google Scholar
• Durhan A, Senlikci A, Kosmaz K, Erguder E, Mercan U, Suleyman M. 2021. An evaluation of the effect of preoperative inflammation-based factors on survival in gastric cancer patients. J Coll Physicians Surg Pak. 31(3):282–287. doi:10.29271/jcpsp.2021.03.282.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G. 2023. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 98(8):1307–1325. doi:10.1002/ajh.26984.
   PubMed Web of Science ®Google Scholar
• Ghahari M, Salari A, Ghafoori Yazdi M, Nowroozi A, Fotovat A, Momeni SA, Nowroozi MR, Amini E. 2022. Association between preoperative De Ritis (AST/ALT) ratio and oncological outcomes following radical cystectomy in patients with urothelial bladder cancer. Clin Genitourin Cancer. 20(2):e89–e93. doi:10.1016/j.clgc.2021.10.007.
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, et al. 1997. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 89(6):2079–2088. doi:10.1182/blood.V89.6.2079.
   PubMed Web of Science ®Google Scholar
• Hara R, Kitahara T, Numata H, Toyosaki M, Watanabe S, Kikkawa E, Ogawa Y, Kawada H, Ando K. 2022. Fetal hemoglobin level predicts lower-risk myelodysplastic syndrome. Int J Hematol. 117(5):684–693. doi:10.1007/s12185-022-03523-5.
   PubMed Web of Science ®Google Scholar
• Hellström-Lindberg E, Tobiasson M, Greenberg P. 2020. Myelodysplastic syndromes: moving towards personalized management. Haematologica. 105(7):1765–1779. doi:10.3324/haematol.2020.248955.
   PubMed Web of Science ®Google Scholar
• Khoury JD, Solary E, Abla O, et al. 2022. The 5th edition of the world health organization classification of Haematolymphoid Tumours: myeloid and histiocytic/Dendritic neoplasms. Leukemia. 36(7):1703–1719. doi:10.1038/s41375-022-01613-1.
   PubMed Web of Science ®Google Scholar
• Knittelfelder O, Delago D, Jakse G, Reinisch S, Partl R, Stranzl-Lawatsch H, Renner W, Langsenlehner T. 2020. The AST/ALT (De Ritis) ratio predicts survival in patients with oral and oropharyngeal cancer. Diagnostics (Basel). 10(11):1–14. doi:10.3390/diagnostics10110973.
   Google Scholar
• Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. 1999. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 130(6):461–470. doi:10.7326/0003-4819-130-6-199903160-00002.
   PubMed Web of Science ®Google Scholar
• Lu TX, Wu S, Cai DY, Hong TT, Zhang Y, Gao HQ, Hua HY, Wu XH. 2019. Prognostic significance of serum aspartic transaminase in diffuse large B-cell lymphoma. BMC Cancer. 19(1):553. doi:10.1186/s12885-019-5758-2.
   PubMedGoogle Scholar
• Mcgowan-Jordan J, Hastings RJ, Moore S. ISCN 2020: An International System for Human Cytogenomic Nomenclature. 2020. 1–237. doi:10.1159/isbn.978-3-318-06867-2.
   Google Scholar
• Otto-Ślusarczyk D, Graboń W, Mielczarek-Puta M. 2016. [Aspartate aminotransferase–key enzyme in the human systemic metabolism]. Postepy Hig Med Dosw (Online). 70:219–230. doi:10.5604/17322693.1197373.
   PubMedGoogle Scholar
• Platzbecker U, Kubasch AS, Homer-Bouthiette C, Prebet T. 2021. Current challenges and unmet medical needs in myelodysplastic syndromes. Leukemia. 35(8):2182–2198. doi:10.1038/s41375-021-01265-7.
   PubMed Web of Science ®Google Scholar
• Riabov V, Mossner M, Stöhr A, Jann JC, Streuer A, Schmitt N, Knaflic A, Nowak V, Weimer N, Obländer J, et al. 2021. High erythroferrone expression in CD71(+) erythroid progenitors predicts superior survival in myelodysplastic syndromes. Br J Haematol. 192(5):879–891. doi:10.1111/bjh.17314.
   PubMed Web of Science ®Google Scholar
• Riedl JM, Posch F, Prager G, Eisterer W, Oehler L, Sliwa T, Wilthoner K, Petzer A, Pichler P, Hubmann E, et al. 2020. The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: post hoc analysis of an Austrian multicenter, noninterventional study. Ther Adv Med Oncol. 12:1758835919900872. doi:10.1177/1758835919900872.
   Web of Science ®Google Scholar
• Saumell S, Fernández-Serrano M, Mesa A, López-Cadenas F, Arenillas L, Alfonso A, Montoro MJ, Molero A, Leoz P, Riego V, et al. 2022. Prognostic impact of micromegakaryocytes in primary myelodysplastic syndromes. Leuk Lymphoma. 63(5):1227–1235. doi:10.1080/10428194.2021.2018581.
   PubMed Web of Science ®Google Scholar
• Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J, Granada I, Hildebrandt B, Slovak ML, Ohyashiki K, et al. 2012. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol: Official J Am Soc Clin Oncol. 30(8):820–829. doi:10.1200/JCO.2011.35.6394.
   PubMed Web of Science ®Google Scholar
• Scheipner L, Smolle MA, Barth D, Posch F, Stotz M, Pichler M, StÖger H, Gerger A, Riedl JM. 2021. The AST/ALT ratio is an independent prognostic marker for disease-free survival in stage II and III colorectal carcinoma. Anticancer Res. 41(1):429–436. doi:10.21873/anticanres.14792.
   PubMed Web of Science ®Google Scholar
• Schindhelm RK, Diamant M, Dekker JM, Tushuizen ME, Teerlink T, Heine RJ. 2006. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev. 22(6):437–443. doi:10.1002/dmrr.666.
   PubMed Web of Science ®Google Scholar
• Shi C, Gong S, Niu T, Li T, Wu A, Zheng X, Yang S, Ouyang G, Mu Q. 2022. The prognostic value of pretherapy peripheral blood inflammatory indices in myelodysplastic syndromes. Front Oncol. 12:877981. doi:10.3389/fonc.2022.877981.
   PubMed Web of Science ®Google Scholar
• Song BH, Son SY, Kim HK, Ha TW, Im JS, Ryu A, Jeon H, Chung HY, Oh JS, Lee CH, et al. 2020. Profiling of metabolic differences between hematopoietic stem cells and acute/Chronic myeloid leukemia. Metabolites. 10(11):1–12. doi:10.3390/metabo10110427.
   Web of Science ®Google Scholar
• Wu J, Zhang Y, Qin T, Xu Z, Qu S, Pan L, Li B, Jia Y, Li C, Wang H, et al. 2022. IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromes. Exp Hematol Oncol. 11(1):73. doi:10.1186/s40164-022-00328-4.
   PubMed Web of Science ®Google Scholar
• Yang L, Venneti S, Nagrath D. 2017. Glutaminolysis: a hallmark of cancer metabolism. Annu Rev Biomed Eng. 19:163–194. doi:10.1146/annurev-bioeng-071516-044546.
   PubMed Web of Science ®Google Scholar